BioPharmSignal logoBioPharmSignal

Biotech News

Artivion Reports Fourth Quarter and Full Year 2025 Financial Results

Artivion (AORT)ArtivionEarnings

Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024. GAAP net income was $2.4 million, or $0.05 per fully

Related news

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

FEMYFEMASYS2026-08-14 20:05 EST

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

PAVMPAVmed2026-08-13 12:00 EST

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

XAIRBeyond Air2026-08-13 11:00 EST

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

ICUSeaStar Medical2026-08-12 20:05 EST

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

View all latest news

Artivion

Aortic-Disease Technologies Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease. Surgical Products The company supplies aortic stent grafts, surgical adhesives, mechanical...

Recent company news

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-06-29 11:00 EST

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

AORTArtivion2026-06-10 20:10 EST

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Stock data

Close
28.08 USD
Market cap
991.26M USD
Exchange
NYSE
Sector
MedTech
Location
United States